Railway Pension Investments Ltd Reduces Holdings in Gilead Sciences, Inc. $GILD

Railway Pension Investments Ltd lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.1% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 1,373,465 shares of the biopharmaceutical company’s stock after selling 58,600 shares during the period. Gilead Sciences makes up 2.1% of Railway Pension Investments Ltd’s investment portfolio, making the stock its 2nd biggest holding. Railway Pension Investments Ltd owned about 0.11% of Gilead Sciences worth $152,276,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Gilead Sciences by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after acquiring an additional 1,893,401 shares during the period. Geode Capital Management LLC boosted its stake in Gilead Sciences by 2.6% during the second quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock worth $3,231,548,000 after buying an additional 727,515 shares in the last quarter. Norges Bank bought a new stake in Gilead Sciences in the 2nd quarter valued at $2,150,268,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after acquiring an additional 11,156,382 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Gilead Sciences by 12.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock valued at $1,541,302,000 after acquiring an additional 1,520,809 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $125.23, for a total value of $313,075.00. Following the transaction, the chief financial officer owned 154,555 shares of the company’s stock, valued at approximately $19,354,922.65. This trade represents a 1.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the sale, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 115,146 shares of company stock worth $14,012,141 in the last ninety days. 0.27% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

GILD has been the topic of a number of recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $135.00 price objective on shares of Gilead Sciences in a report on Friday, October 31st. Truist Financial began coverage on Gilead Sciences in a research report on Monday, November 24th. They issued a “buy” rating and a $140.00 price target on the stock. Scotiabank initiated coverage on Gilead Sciences in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price objective for the company. Argus boosted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Finally, Sanford C. Bernstein reiterated an “outperform” rating on shares of Gilead Sciences in a research report on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $130.65.

Gilead Sciences Price Performance

Shares of GILD stock opened at $125.85 on Friday. Gilead Sciences, Inc. has a 1 year low of $88.57 and a 1 year high of $128.70. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The firm’s 50 day moving average is $119.87 and its 200-day moving average is $114.59. The firm has a market capitalization of $156.13 billion, a price-to-earnings ratio of 25.07, a PEG ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. During the same quarter last year, the business posted $2.02 earnings per share. Gilead Sciences’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio is 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.